Literature DB >> 27130558

Persistent bone marrow depression following short-term treatment with temozolomide.

Kathrine Vandraas1, Geir Erland Tjønnfjord2, Tom Børge Johannesen1, Petter Brandal1.   

Abstract

Temozolomide (TMZ) is, in combination with radiotherapy (RT), the treatment of choice for glioblastoma multiforme. Although generally well tolerated, haematological side effects are observed in approximately 1-10% of patients receiving TMZ. We report a case of a patient who developed severe bone marrow failure (BMF) after only 3 weeks of concomitant TMZ. The BMF was grave with no signs of improvement for 12 months, resulting in more than 100 transfusions of blood cells. 2016 BMJ Publishing Group Ltd.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27130558      PMCID： PMC4854153          DOI： 10.1136/bcr-2016-215797

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  13 in total

1.  Aplastic anaemia in patient with glioblastoma multiforme treated with temozolomide.

Authors:  J Lee Villano; Cindy A Collins; Elisabet E Manasanch; Charulata Ramaprasad; Koen van Besien
Journal:  Lancet Oncol       Date:  2006-05       Impact factor: 41.316

2.  A rare case of aplastic anemia caused by temozolomide.

Authors:  Benjamin J George; Jessica B Eichinger; Thomas J Richard
Journal:  South Med J       Date:  2009-09       Impact factor: 0.954

Review 3.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009.

Authors:  Therese A Dolecek; Jennifer M Propp; Nancy E Stroup; Carol Kruchko
Journal:  Neuro Oncol       Date:  2012-11       Impact factor: 12.300

Review 4.  Targeted modulation of MGMT: clinical implications.

Authors:  Lili Liu; Stanton L Gerson
Journal:  Clin Cancer Res       Date:  2006-01-15       Impact factor: 12.531

5.  Aplastic anemia with concurrent temozolomide treatment in a patient with glioblastoma multiforme.

Authors:  J Oh; G J Kutas; P Davey; M Morrison; J R Perry
Journal:  Curr Oncol       Date:  2010-08       Impact factor: 3.677

6.  Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors.

Authors:  Terri S Armstrong; Yumei Cao; Michael E Scheurer; Elizabeth Vera-Bolaños; Rochelle Manning; Mehmet F Okcu; Melissa Bondy; Renke Zhou; Mark R Gilbert
Journal:  Neuro Oncol       Date:  2009-12       Impact factor: 12.300

Review 7.  Alkylation damage in DNA and RNA--repair mechanisms and medical significance.

Authors:  Finn Drabløs; Emadoldin Feyzi; Per Arne Aas; Cathrine B Vaagbø; Bodil Kavli; Marit S Bratlie; Javier Peña-Diaz; Marit Otterlei; Geir Slupphaug; Hans E Krokan
Journal:  DNA Repair (Amst)       Date:  2004-11-02

Review 8.  Temozolomide-related hematologic toxicity.

Authors:  Claudia Scaringi; Vitaliana De Sanctis; Giuseppe Minniti; Riccardo Maurizi Enrici
Journal:  Onkologie       Date:  2013-07-08

9.  A population-based study on the effect of temozolomide in the treatment of glioblastoma multiforme.

Authors:  Pål A Rønning; Eirik Helseth; Torstein R Meling; Tom B Johannesen
Journal:  Neuro Oncol       Date:  2012-08-06       Impact factor: 12.300

Review 10.  Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity.

Authors:  Monika E Hegi; Lili Liu; James G Herman; Roger Stupp; Wolfgang Wick; Michael Weller; Minesh P Mehta; Mark R Gilbert
Journal:  J Clin Oncol       Date:  2008-09-01       Impact factor: 44.544
View more
  2 in total

1.  Long-lasting Thrombocytopenia after Transient Pancytopenia Induced by Short-Term Concomitant Radiotherapy and Temozolomide.

Authors:  Aleksandar Stepanović; Marina Nikitović; Andrija Bogdanović; Danica Grujičić
Journal:  Eur J Case Rep Intern Med       Date:  2020-07-07

2.  Hematological adverse events in the management of glioblastoma.

Authors:  Catherine R Garcia; Zin W Myint; Rani Jayswal; Chi Wang; Rachael M Morgan; Allison R Butts; Heidi L Weiss; John L Villano
Journal:  J Neurooncol       Date:  2021-11-24       Impact factor: 4.130
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.